Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story. (3rd July 2020)

• Record Type: Journal Article
• Authors: Triche, Lisa; Yarbrough, Angela; Roth, Michael; Ying, Anita; Wells, Robert
• Is Part Of: Pediatric hematology and oncology. Volume 37:Number 5(2020)
• Page Start: 375
• Page End: 379
• Publication Date: 2020-07-03
• Subjects: Chronic myeloid leukemia -- tyrosine kinase inhibitor -- growth hormone -- major molecular remission; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.1080/08880018.2020.1751755
• Languages: English
• ISSNs: 0888-0018

Abstract

Abstract: We report a patient who developed chronic myelogenous leukemia (CML) at 12 months of age. She was treated aggressively with stem cell transplant (SCT), interferon, donor lymphocytes and imatinib, with subsequent molecular progression. She received dasatinib, achieving a complete molecular response. Dasatinib was discontinued at 3 years but she had a molecular recurrence. Dasatinib was restarted and continued for 5 additional years with a second major molecular remission (MMR). While on dasatinib therapy she suffered growth failure and was treated with concurrent growth hormone (GH). After discontinuing dasatinib and GH, catch-up growth continues and she remains in MMR. Discontinuation of TKI therapy and the toxicity of long-term TKI therapy is discussed.